Recent Surge for Intellectual Property & Patents in Psychedelic Therapies & Drug Development
News provided by
Share this article
Financialnewsmedia.com News Commentary
PALM BEACH, Fla., June 15, 2021 /PRNewswire/ The modern psychedelic renaissance has empirically proven that psychedelic drugs are going to revolutionize mental health treatment. Before these incredibly promising medicines can get to the people who need them the most, they must pass through the extensive drug development pipeline, where IP & Patents are crucial. It seems that a week doesn t go by without a psychedelic company saying it has filed for a new patent. An informative article on Microdose explains the reasons why psychedelic companies are pursuing these patents. First, the plants that the medicines are based on can t be patented. Products in nature belong to the public and thus can t be patented. Microdose wrote, One company cannot claim it as intellectual property to exclusively profit from it. How
4 Penny Stocks to Watch Following the Fed Meeting and Powell s Remarks | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Recent Surge for Intellectual Property & Patents in Psychedelic Therapies & Drug Development
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research
MindMed (NASDAQ:MNMD) (NEO: MMED) released a series of new announcements following the company’s Q1 earnings report.
The company reported Thursday that it had obtained authorization from one of the local Swiss ethics committees to conduct its first clinical trial on mescaline.
The research is scheduled to begin in May at the University Hospital Basel Liechti Lab in Basel, Switzerland.
The study will examine the effects of various doses of mescaline and “the role of the serotonin 5-HT2A receptor in a mescaline-induced altered state of consciousness.”